Cancer: Drugs

Department of Health written question – answered on 4th February 2015.

Alert me about debates like this

Photo of Lord Hunt of Kings Heath Lord Hunt of Kings Heath Shadow Spokesperson (Health), Shadow Deputy Leader of the House of Lords

To ask Her Majesty’s Government what processes have been put in place to ensure equitable access to molecular diagnostics across the National Health Service for medicines listed on the Cancer Drugs Fund.

Photo of Earl Howe Earl Howe The Parliamentary Under-Secretary of State for Health

NHS England has advised that it is not the sole commissioner of molecular diagnostic testing.

Work is currently underway to clarify legacy arrangements for how such tests are currently commissioned and ensure alignment with the National Tariff payment rules. It is NHS England’s intention to ensure that a whole systems approach to the future commissioning of diagnostics within specialised services and by clinical commissioning groups forms part of a clinical and scientific strategy informing new models of care and the implementation of the Five Year Forward View.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.